{"transactions":[{"id":4620268,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-09-17T00:00:31.000Z","date":"2026-09-14","kind":"grant","planned":false,"acquired":true,"shares":471,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Company's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant."}],"balance_after":471,"derivative":{"underlying":"Common Stock","underlying_shares":471},"source":{"system":"sec-edgar","filing":"0001532023-26-000002","document":"wk-form4_1789603228.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1711279/000153202326000002/wk-form4_1789603228.xml","form_type":"4"}},{"id":4620267,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-17T00:00:31.000Z","date":"2026-09-14","kind":"grant","planned":false,"acquired":true,"shares":1187,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant."}],"balance_after":1187,"derivative":{"exercise_price":340.03,"expiration_date":"2036-09-13","underlying":"Common Stock","underlying_shares":1187},"source":{"system":"sec-edgar","filing":"0001532023-26-000002","document":"wk-form4_1789603228.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711279/000153202326000002/wk-form4_1789603228.xml","form_type":"4"}},{"id":1024132,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-03T19:45:08.000Z","date":"2025-10-01","kind":"grant","planned":false,"acquired":true,"shares":286734,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option grant is an annual stock option grant under the Issuer's Non-Employee Director Compensation Policy and the Issuer's 2024 Equity Incentive Plan (the \"2024 Plan\") and shall fully vest on October 1, 2026, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control."}],"balance_after":286734,"derivative":{"exercise_price":1.04,"expiration_date":"2035-10-01","underlying":"Common Stock","underlying_shares":286734},"source":{"system":"sec-edgar","filing":"0001649989-25-000007","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1532023/000164998925000007/primary_doc.xml","form_type":"4"}},{"id":1099295,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-30T22:23:44.000Z","date":"2025-06-30","kind":"grant","planned":false,"acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were awarded on June 30, 2025 and vest in equal monthly tranches over a one-year period."}],"balance_after":5000,"derivative":{"exercise_price":137.46,"expiration_date":"2035-06-30","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001532023-25-000005","document":"wk-form4_1751322218.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711279/000153202325000005/wk-form4_1751322218.xml","form_type":"4"}},{"id":1280296,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-06T20:06:31.000Z","date":"2025-02-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each Issuer restricted stock award held by a non-employee member of the Issuer board then outstanding and not vested was canceled and converted into the right to receive the Per Share Price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-25-015688","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000095017025015688/ownership.xml","form_type":"4"}},{"id":1280295,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-06T20:06:31.000Z","date":"2025-02-04","kind":"other","planned":false,"acquired":false,"shares":30106,"price":3.65,"value":109886.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported securities were disposed of pursuant to the terms of the Amended and Restated Agreement and Plan of Merger, dated as of December 7, 2024 (as subsequently amended, the \"Merger Agreement\"), by and among the Issuer, Crown Laboratories, Inc., a Delaware corporation (\"Parent\"), Reba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent (\"Merger Sub,\" and together with Parent, the \"Buyer Parties\"), pursuant to which Merger Sub completed a cash tender offer (the \"Offer\") for all of the issued and outstanding shares of common stock, par value $0.001 per share (the \"Shares\"), of the Issuer at a purchase price of $3.65 per share, without interest, and subject to any applicable withholding taxes (the \"Per Share Price\"). These Issuer Shares were tendered for purchase pursuant to the Offer."}],"balance_after":15000,"source":{"system":"sec-edgar","filing":"0000950170-25-015688","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000095017025015688/ownership.xml","form_type":"4"}},{"id":1391538,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-03T21:22:40.000Z","date":"2024-10-01","kind":"grant","planned":false,"acquired":true,"shares":71169,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option grant was made under the 2024 Plan and shall fully vest on October 1, 2025, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control."}],"balance_after":71169,"derivative":{"exercise_price":5.22,"expiration_date":"2034-10-01","underlying":"Common Stock","underlying_shares":71169},"source":{"system":"sec-edgar","filing":"0001415889-24-024711","document":"form4-10042024_011036.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1532023/000141588924024711/form4-10042024_011036.xml","form_type":"4"}},{"id":1391537,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-03T21:22:40.000Z","date":"2024-10-01","kind":"grant","planned":false,"acquired":true,"shares":56636,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option grant is an annual stock option grant under the Issuer's Non-Employee Director Compensation Policy and the Issuer's 2024 Equity Incentive Plan (the \"2024 Plan\") and shall fully vest on October 1, 2025, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control."}],"balance_after":56636,"derivative":{"exercise_price":5.22,"expiration_date":"2034-10-01","underlying":"Common Stock","underlying_shares":56636},"source":{"system":"sec-edgar","filing":"0001415889-24-024711","document":"form4-10042024_011036.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1532023/000141588924024711/form4-10042024_011036.xml","form_type":"4"}},{"id":1465832,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-01T23:37:34.000Z","date":"2024-06-30","kind":"grant","planned":false,"acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were awarded on June 30, 2024 and vest in equal monthly tranches over a one-year period."}],"balance_after":5000,"derivative":{"exercise_price":183.64,"expiration_date":"2034-06-30","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001532023-24-000010","document":"wk-form4_1719877048.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711279/000153202324000010/wk-form4_1719877048.xml","form_type":"4"}},{"id":1505512,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-22T22:17:14.000Z","date":"2024-05-20","kind":"exercise","planned":false,"acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options were awarded on March 1, 2019 and vested monthly over a three-year period."}],"balance_after":0,"derivative":{"exercise_price":22.75,"expiration_date":"2029-03-01","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001532023-24-000008","document":"wk-form4_1716416222.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1711279/000153202324000008/wk-form4_1716416222.xml","form_type":"4"}},{"id":1505511,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-22T22:17:14.000Z","date":"2024-05-20","kind":"sale","planned":false,"acquired":false,"shares":1980,"price":165.7576,"value":328200.048,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction was executed in multiple trades ranging from $165.160 to $166.000. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001532023-24-000008","document":"wk-form4_1716416222.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1711279/000153202324000008/wk-form4_1716416222.xml","form_type":"4"}},{"id":1505510,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-22T22:17:14.000Z","date":"2024-05-20","kind":"sale","planned":false,"acquired":false,"shares":7090,"price":164.3413,"value":1165179.817,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades ranging from $164.085 to $164.850. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":1980,"source":{"system":"sec-edgar","filing":"0001532023-24-000008","document":"wk-form4_1716416222.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1711279/000153202324000008/wk-form4_1716416222.xml","form_type":"4"}},{"id":1505509,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-22T22:17:14.000Z","date":"2024-05-20","kind":"sale","planned":false,"acquired":false,"shares":10930,"price":163.7063,"value":1789309.859,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The transaction was executed in multiple trades ranging from $163.080 to $164.065. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":9070,"source":{"system":"sec-edgar","filing":"0001532023-24-000008","document":"wk-form4_1716416222.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1711279/000153202324000008/wk-form4_1716416222.xml","form_type":"4"}},{"id":1505508,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-22T22:17:14.000Z","date":"2024-05-20","kind":"exercise","planned":false,"acquired":true,"shares":20000,"price":22.75,"value":455000.0,"ownership":{"direct":true},"balance_after":20000,"source":{"system":"sec-edgar","filing":"0001532023-24-000008","document":"wk-form4_1716416222.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711279/000153202324000008/wk-form4_1716416222.xml","form_type":"4"}},{"id":1528115,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2024-05-03T08:44:31.000Z","date":"2024-05-01","kind":"grant","planned":false,"acquired":true,"shares":23458,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the stock option shall vest on the earlier of (a) the one year anniversary, May 1, 2025 and (b) the day immediately prior to the date of the Company's next annual stockholder meeting, subject to the Director's Continuous Service through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy."}],"balance_after":23458,"derivative":{"exercise_price":3.795,"expiration_date":"2034-04-30","underlying":"Common Stock","underlying_shares":23458},"source":{"system":"sec-edgar","filing":"0001479290-24-000086","document":"wk-form4_1714740263.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929024000086/wk-form4_1714740263.xml","form_type":"4"}},{"id":1528114,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-03T08:44:31.000Z","date":"2024-05-01","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an annual restricted stock award (the \"RSA\") granted pursuant to the Company's Amended and Restated Non-Employee Director Compensation Policy (the \"Compensation Policy\").  The shares underlying the RSA shall vest on the earlier of (a) the one year anniversary, May 1, 2025 and (b) the day immediately prior to the date of the Company's next annual stockholder meeting, subject to the Director's Continuous Service (as defined in the Company's 2014 Equity Incentive Plan (the \"Plan\")) through such vesting date."}],"balance_after":45106,"source":{"system":"sec-edgar","filing":"0001479290-24-000086","document":"wk-form4_1714740263.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929024000086/wk-form4_1714740263.xml","form_type":"4"}},{"id":1586098,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-08T16:13:00.000Z","date":"2024-03-07","kind":"grant","planned":false,"acquired":true,"shares":94441,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted under the Issuer's 2015 Equity Incentive Plan (the \"2015 Plan\") and shall fully vest on the earlier of (i) March 7, 2025; or (ii) the date of the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control."}],"balance_after":94441,"derivative":{"exercise_price":0.41,"expiration_date":"2034-03-07","underlying":"Common Stock","underlying_shares":94441},"source":{"system":"sec-edgar","filing":"0001415889-24-007335","document":"form4-03082024_090352.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1532023/000141588924007335/form4-03082024_090352.xml","form_type":"4"}},{"id":1763354,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-10-06T08:16:11.000Z","date":"2023-10-04","kind":"grant","planned":false,"acquired":true,"shares":370282,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted under the 2015 Plan in lieu of $77,500 cash fees payable under the Issuer's non-employee Director compensation program and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2024, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan."}],"balance_after":370282,"derivative":{"exercise_price":0.24,"expiration_date":"2033-10-04","underlying":"Common Stock","underlying_shares":370282},"source":{"system":"sec-edgar","filing":"0001209191-23-052271","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1532023/000120919123052271/doc4.xml","form_type":"4"}},{"id":1839751,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-03T20:16:03.000Z","date":"2023-06-30","kind":"grant","planned":false,"acquired":true,"shares":6800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were awarded on June 30, 2023 and vest in equal monthly tranches over a one-year period."}],"balance_after":6800,"derivative":{"exercise_price":117.4,"expiration_date":"2033-06-30","underlying":"Common Stock","underlying_shares":6800},"source":{"system":"sec-edgar","filing":"0001711279-23-000049","document":"wk-form4_1688415354.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711279/000171127923000049/wk-form4_1688415354.xml","form_type":"4"}},{"id":1902657,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2023-05-05T17:15:32.000Z","date":"2023-05-03","kind":"grant","planned":false,"acquired":true,"shares":5915,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the stock option shall vest on the earlier of (a) the one year anniversary, May 3, 2024 and (b) the day immediately prior to the date of the Company's next annual stockholder meeting, subject to Mr. Gangolli's Continuous Service through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy."}],"balance_after":5915,"derivative":{"exercise_price":33.61,"expiration_date":"2033-05-02","underlying":"Common Stock","underlying_shares":5915},"source":{"system":"sec-edgar","filing":"0001479290-23-000064","document":"wf-form4_168332131583022.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929023000064/wf-form4_168332131583022.xml","form_type":"4"}},{"id":1902656,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-05T17:15:32.000Z","date":"2023-05-03","kind":"grant","planned":false,"acquired":true,"shares":3534,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an annual restricted stock award (the \"RSA\") granted pursuant to the Company's Amended and Restated Non-Employee Director Compensation Policy (the \"Compensation Policy\"). The shares underlying the RSA shall vest on the earlier of (a) the one year anniversary, May 3, 2024 and (b) the day immediately prior to the date of the Company's next annual stockholder meeting, subject to Mr. Gangolli's Continuous Service (as defined in the Company's 2014 Equity Incentive Plan (the \"Plan\")) through such vesting date."}],"balance_after":30106,"source":{"system":"sec-edgar","filing":"0001479290-23-000064","document":"wf-form4_168332131583022.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929023000064/wf-form4_168332131583022.xml","form_type":"4"}},{"id":1933774,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-31T17:46:28.000Z","date":"2023-03-29","kind":"grant","planned":false,"acquired":true,"shares":41065,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted under the Issuer's 2015 Equity Incentive Plan (the \"2015 Plan\") and shall fully vest on the earlier of (i) March 29,2024; or (ii) the date of the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control."}],"balance_after":41065,"derivative":{"exercise_price":1.05,"expiration_date":"2033-03-29","underlying":"Common Stock","underlying_shares":41065},"source":{"system":"sec-edgar","filing":"0001209191-23-021907","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1532023/000120919123021907/doc4.xml","form_type":"4"}},{"id":2140211,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-07T16:36:38.000Z","date":"2022-10-05","kind":"grant","acquired":true,"shares":74398,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted under the 2015 Plan in lieu of $77,500 cash fees payable under the Issuer's non-employee Director compensation program and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2023, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan."}],"balance_after":74398,"derivative":{"exercise_price":1.25,"expiration_date":"2032-10-05","underlying":"Common Stock","underlying_shares":74398},"source":{"system":"sec-edgar","filing":"0001209191-22-053119","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1532023/000120919122053119/doc4.xml","form_type":"4"}},{"id":2217361,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-07-01T20:05:49.000Z","date":"2022-06-30","kind":"grant","acquired":true,"shares":6800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were awarded on June 30, 2022 and vest in equal monthly tranches over a one-year period."}],"balance_after":6800,"derivative":{"exercise_price":65.66,"expiration_date":"2032-06-30","underlying":"Common Stock","underlying_shares":6800},"source":{"system":"sec-edgar","filing":"0001711279-22-000034","document":"wf-form4_165670592393510.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711279/000171127922000034/wf-form4_165670592393510.xml","form_type":"4"}},{"id":2271983,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2022-05-13T18:14:38.000Z","date":"2022-05-04","kind":"grant","acquired":true,"shares":10756,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the stock option shall vest on the one year anniversary, May 4, 2023, subject to Mr. Gangolli's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) through such vesting date. The stock option represents an annual grant pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy."}],"balance_after":10756,"derivative":{"exercise_price":18.12,"expiration_date":"2032-05-03","underlying":"Common Stock","underlying_shares":10756},"source":{"system":"sec-edgar","filing":"0001479290-22-000069","document":"wf-form4a_165248002605949.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929022000069/wf-form4a_165248002605949.xml","form_type":"4/A","original_submission_date":"2022-05-06"}},{"id":2279278,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2022-05-06T18:18:56.000Z","date":"2022-05-04","kind":"grant","acquired":true,"shares":11343,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the stock option shall vest on the one year anniversary, May 4, 2023, subject to Mr. Gangolli's Continuous Service (as defined in the Plan) through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy."}],"balance_after":11343,"derivative":{"exercise_price":18.12,"expiration_date":"2032-05-03","underlying":"Common Stock","underlying_shares":11343},"source":{"system":"sec-edgar","filing":"0001479290-22-000061","document":"wf-form4_165187552266324.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929022000061/wf-form4_165187552266324.xml","form_type":"4"}},{"id":2279277,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-06T18:18:56.000Z","date":"2022-05-04","kind":"grant","acquired":true,"shares":6059,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an annual restricted stock award (the \"RSA\") granted pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the \"Compensation Policy\").  The shares underlying the RSA shall vest on the one year anniversary, May 4, 2023, subject to Mr. Gangolli's Continuous Service (as defined the Issuer's 2014 Equity Incentive Plan (the \"Plan\")) through such vesting date."}],"balance_after":26572,"source":{"system":"sec-edgar","filing":"0001479290-22-000061","document":"wf-form4_165187552266324.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929022000061/wf-form4_165187552266324.xml","form_type":"4"}},{"id":2318630,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-24T17:42:38.000Z","date":"2022-03-23","kind":"grant","acquired":true,"shares":21878,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted under the Issuer's 2015 Equity Incentive Plan (the \"2015 Plan\") and shall fully vest on the earlier of (i) March 23,2023; or (ii) the date of the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control."}],"balance_after":21878,"derivative":{"exercise_price":1.92,"expiration_date":"2032-03-23","underlying":"Common Stock","underlying_shares":21878},"source":{"system":"sec-edgar","filing":"0001209191-22-020955","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1532023/000120919122020955/doc4.xml","form_type":"4"}},{"id":2546188,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-07T17:07:19.000Z","date":"2021-10-05","kind":"grant","acquired":true,"shares":44466,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted under the 2015 Plan in lieu of $77,500 cash fees payable under the Issuer's non-employee Director compensation program and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2022, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan."}],"balance_after":44466,"derivative":{"exercise_price":2.12,"expiration_date":"2031-10-05","underlying":"Common Stock","underlying_shares":44466},"source":{"system":"sec-edgar","filing":"0001209191-21-059952","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1532023/000120919121059952/doc4.xml","form_type":"4"}},{"id":2644949,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-07-02T15:33:51.000Z","date":"2021-06-30","kind":"grant","acquired":true,"shares":6800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were awarded on June 30, 2021 and vest in equal monthly tranches over a one-year period."}],"balance_after":6800,"derivative":{"exercise_price":68,"expiration_date":"2031-06-30","underlying":"Common Stock","underlying_shares":6800},"source":{"system":"sec-edgar","filing":"0001711279-21-000018","document":"wf-form4_162524001713056.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711279/000171127921000018/wf-form4_162524001713056.xml","form_type":"4"}},{"id":2723084,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2021-05-07T19:06:43.000Z","date":"2021-05-05","kind":"grant","acquired":true,"shares":7551,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the stock option shall vest on the one year anniversary, May 5, 2022, subject to Mr. Gangolli's Continuous Service (as defined in the Plan) through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy."}],"balance_after":7551,"derivative":{"exercise_price":27.91,"expiration_date":"2031-05-04","underlying":"Common Stock","underlying_shares":7551},"source":{"system":"sec-edgar","filing":"0001479290-21-000108","document":"wf-form4_162042878677999.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929021000108/wf-form4_162042878677999.xml","form_type":"4"}},{"id":2723083,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-07T19:06:43.000Z","date":"2021-05-05","kind":"grant","acquired":true,"shares":4013,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an annual restricted stock award (the \"RSA\") granted pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the \"Compensation Policy\").  The shares underlying the RSA shall vest on the one year anniversary, May 5, 2022, subject to Mr. Gangolli's Continuous Service (as defined the Issuer's 2014 Equity Incentive Plan (the \"Plan\")) through such vesting date."}],"balance_after":20513,"source":{"system":"sec-edgar","filing":"0001479290-21-000108","document":"wf-form4_162042878677999.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929021000108/wf-form4_162042878677999.xml","form_type":"4"}},{"id":2770285,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-26T18:09:07.000Z","date":"2021-03-24","kind":"grant","acquired":true,"shares":20873,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted under the Issuer's 2015 Equity Incentive Plan (the \"2015 Plan\") and shall vest in full on March 24, 2022, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer through such event."}],"balance_after":20873,"derivative":{"exercise_price":2.27,"expiration_date":"2031-03-24","underlying":"Common Stock","underlying_shares":20873},"source":{"system":"sec-edgar","filing":"0001209191-21-023284","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1532023/000120919121023284/doc4.xml","form_type":"4"}},{"id":3012512,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-10-05T18:41:59.000Z","date":"2020-10-05","kind":"grant","acquired":true,"shares":150748,"price":0.5141,"value":77499.5468,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted under the 2015 Plan in lieu of $77,500 cash fees payable under the Issuer's non-employee Director compensation program and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2021, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan."}],"balance_after":150748,"derivative":{"exercise_price":0.7052,"expiration_date":"2030-10-05","underlying":"Common Stock","underlying_shares":150748},"source":{"system":"sec-edgar","filing":"0001209191-20-053865","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1532023/000120919120053865/doc4.xml","form_type":"4"}},{"id":3064904,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-08-08T00:22:37.000Z","date":"2020-06-30","kind":"grant","acquired":true,"shares":6800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were awarded on June 30, 2020 and vest in equal monthly tranches over a one-year period."}],"balance_after":6800,"derivative":{"exercise_price":41.42,"expiration_date":"2030-06-29","underlying":"Common Stock","underlying_shares":6800},"source":{"system":"sec-edgar","filing":"0000899243-20-021813","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711279/000089924320021813/doc4.xml","form_type":"4"}},{"id":3078562,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-07-21T18:05:47.000Z","date":"2020-07-17","kind":"grant","acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted under the Issuer's 2015 Equity Incentive Plan (the \"2015 Plan\") and shall vest in full on July 17, 2021, subject to the\nReporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer through such event."}],"balance_after":125000,"derivative":{"exercise_price":1.58,"expiration_date":"2030-07-17","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001209191-20-043217","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1532023/000120919120043217/doc4.xml","form_type":"4"}},{"id":3088243,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-07-06T20:40:01.000Z","date":"2020-07-01","kind":"grant","acquired":true,"shares":35006,"price":0.9853,"value":34491.4118,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted under the Issuer's 2015 Equity Incentive Plan (the \"2015 Plan\") in lieu of $34,491.76 cash fees payable under the Issuer's non-employee Director compensation program, and vest on the last day of the remaining fiscal quarter such that they are vested in full on September 30, 2020, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan."}],"balance_after":35006,"derivative":{"exercise_price":1.28,"expiration_date":"2030-07-01","underlying":"Common Stock","underlying_shares":35006},"source":{"system":"sec-edgar","filing":"0001209191-20-041363","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1532023/000120919120041363/doc4.xml","form_type":"4"}},{"id":3147215,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2020-05-15T18:33:41.000Z","date":"2020-05-14","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the stock option shall vest on May 14, 2021, the one year anniversary from the grant date, subject to Mr. Gangolli's Continuous Service (as defined in the Plan) through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy."}],"balance_after":12000,"derivative":{"exercise_price":19.4,"expiration_date":"2030-05-13","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001479290-20-000064","document":"wf-form4_158958200371566.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929020000064/wf-form4_158958200371566.xml","form_type":"4"}},{"id":3147214,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-15T18:33:41.000Z","date":"2020-05-14","kind":"grant","acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an annual restricted stock award (the \"RSA\") granted pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the \"Compensation Policy\").  The shares underlying the RSA shall vest on May 14, 2021, the one year anniversary from the grant date, subject to Mr. Gangolli's Continuous Service (as defined the Issuer's 2014 Equity Incentive Plan (the \"Plan\")) through such vesting date."}],"balance_after":16500,"source":{"system":"sec-edgar","filing":"0001479290-20-000064","document":"wf-form4_158958200371566.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929020000064/wf-form4_158958200371566.xml","form_type":"4"}},{"id":3172201,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-04-21T18:39:44.000Z","date":"2020-04-20","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in three equal annual installments such that the stock option will be fully vested as of the third anniversary of the grant date, subject to (x) the Reporting Person's Continuous Service to the Issuer through such vesting date and (y) acceleration upon a Change in Control."}],"balance_after":25000,"derivative":{"exercise_price":0.72,"expiration_date":"2030-04-20","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-20-025303","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1532023/000120919120025303/doc4.xml","form_type":"4"}},{"id":3527527,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, North America"}}],"security":"Stock Options","published_at":"2019-05-14T21:00:24.000Z","date":"2019-05-10","kind":"exercise","acquired":false,"shares":6,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.30 U.S. Dollars as of May 10, 2019."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F14","text":"These stock options will originally vest on June 24, 2019. Stock options to acquire 6 ordinary shares were accelerated."}],"balance_after":10603,"derivative":{"exercise_price":0.0013,"expiration_date":"2019-12-24","underlying":"Ordinary Shares","underlying_shares":6},"source":{"system":"sec-edgar","filing":"0000899243-19-013509","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319013509/doc4.xml","form_type":"4"}},{"id":3527526,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, North America"}}],"security":"Stock Options","published_at":"2019-05-14T21:00:24.000Z","date":"2019-05-10","kind":"exercise","acquired":false,"shares":192755,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The exercise price was previously reported to be $3.3461 on the Reporting Person's form 3 filed with the SEC on October 1, 2018 due to an administrative error."}],"balance_after":0,"derivative":{"exercise_price":3.72,"exercise_date":"2019-02-15","expiration_date":"2026-02-15","underlying":"Ordinary Shares","underlying_shares":192755},"source":{"system":"sec-edgar","filing":"0000899243-19-013509","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319013509/doc4.xml","form_type":"4"}},{"id":3527525,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, North America"}}],"security":"Stock Options","published_at":"2019-05-14T21:00:24.000Z","date":"2019-05-10","kind":"exercise","acquired":false,"shares":75369,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price was previously reported to be $8.7364 on the Reporting Person's form 3 filed with the SEC on October 1, 2018 due to an administrative error."}],"balance_after":0,"derivative":{"exercise_price":10.61,"exercise_date":"2018-06-24","expiration_date":"2025-06-24","underlying":"Ordinary Shares","underlying_shares":75369},"source":{"system":"sec-edgar","filing":"0000899243-19-013509","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319013509/doc4.xml","form_type":"4"}},{"id":3527524,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, North America"}}],"security":"Stock Options","published_at":"2019-05-14T21:00:24.000Z","date":"2019-05-10","kind":"exercise","acquired":false,"shares":10788,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.30 U.S. Dollars as of May 10, 2019."}],"balance_after":0,"derivative":{"exercise_price":0.0013,"exercise_date":"2019-01-06","expiration_date":"2020-03-15","underlying":"Ordinary Shares","underlying_shares":10788},"source":{"system":"sec-edgar","filing":"0000899243-19-013509","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319013509/doc4.xml","form_type":"4"}},{"id":3527523,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, North America"}}],"security":"Stock Options","published_at":"2019-05-14T21:00:24.000Z","date":"2019-05-10","kind":"exercise","acquired":false,"shares":365591,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.30 U.S. Dollars as of May 10, 2019."}],"balance_after":0,"derivative":{"exercise_price":0.0013,"exercise_date":"2019-02-15","expiration_date":"2020-03-15","underlying":"Ordinary Shares","underlying_shares":365591},"source":{"system":"sec-edgar","filing":"0000899243-19-013509","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319013509/doc4.xml","form_type":"4"}},{"id":3527522,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, North America"}}],"security":"Stock Options","published_at":"2019-05-14T21:00:24.000Z","date":"2019-05-10","kind":"exercise","acquired":false,"shares":27419,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.30 U.S. Dollars as of May 10, 2019."}],"balance_after":0,"derivative":{"exercise_price":0.0013,"exercise_date":"2019-02-15","expiration_date":"2020-03-15","underlying":"Ordinary Shares","underlying_shares":27419},"source":{"system":"sec-edgar","filing":"0000899243-19-013509","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319013509/doc4.xml","form_type":"4"}},{"id":3527521,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, North America"}}],"security":"Ordinary Shares","published_at":"2019-05-14T21:00:24.000Z","date":"2019-05-10","kind":"sale","acquired":false,"shares":10788,"price":15.19,"value":163869.72,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Represented by ADSs. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 8, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The price reported in Column 4 is price per ordinary share converted from price per ADS ($182.32 per ADS)."}],"balance_after":106548,"source":{"system":"sec-edgar","filing":"0000899243-19-013509","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319013509/doc4.xml","form_type":"4"}},{"id":3527520,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, North America"}}],"security":"Ordinary Shares","published_at":"2019-05-14T21:00:24.000Z","date":"2019-05-10","kind":"sale","acquired":false,"shares":31368,"price":15.12,"value":474284.16,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Represented by ADSs. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 8, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported in Column 4 is a weighted average price per ordinary share ($181.46 per ADS). These shares were sold in multiple transactions at prices ranging from $181.28 per ADS (or $15.11 per ordinary share) to $181.65 per ADS (or $15.14 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":117336,"source":{"system":"sec-edgar","filing":"0000899243-19-013509","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319013509/doc4.xml","form_type":"4"}},{"id":3527519,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, North America"}}],"security":"Ordinary Shares","published_at":"2019-05-14T21:00:24.000Z","date":"2019-05-10","kind":"sale","acquired":false,"shares":12048,"price":15.03,"value":181081.44,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Represented by ADSs. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 8, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The price reported in Column 4 is a weighted average price per ordinary share ($180.36 per ADS). These shares were sold in multiple transactions at prices ranging from $180.13 per ADS (or $15.01 per ordinary share) to $180.44 per ADS (or $15.04 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":148704,"source":{"system":"sec-edgar","filing":"0000899243-19-013509","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319013509/doc4.xml","form_type":"4"}},{"id":3527518,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, North America"}}],"security":"Ordinary Shares","published_at":"2019-05-14T21:00:24.000Z","date":"2019-05-10","kind":"sale","acquired":false,"shares":145164,"price":14.96,"value":2171653.44,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Represented by ADSs. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 8, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price per ordinary share ($179.49 per ADS). These shares were sold in multiple transactions at prices ranging from $179.07 per ADS (or $14.92 per ordinary share) to $180.01 per ADS (or $15.00 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":160752,"source":{"system":"sec-edgar","filing":"0000899243-19-013509","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319013509/doc4.xml","form_type":"4"}},{"id":3527517,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, North America"}}],"security":"Ordinary Shares","published_at":"2019-05-14T21:00:24.000Z","date":"2019-05-10","kind":"sale","acquired":false,"shares":208260,"price":14.88,"value":3098908.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Represented by ADSs. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 8, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price per ordinary share ($178.60 per ADS). These shares were sold in multiple transactions at prices ranging from $178.02 per ADS (or $14.84 per ordinary share) to $179.00 per ADS (or $14.92 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":305916,"source":{"system":"sec-edgar","filing":"0000899243-19-013509","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319013509/doc4.xml","form_type":"4"}},{"id":3527516,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, North America"}}],"security":"Ordinary Shares","published_at":"2019-05-14T21:00:24.000Z","date":"2019-05-10","kind":"sale","acquired":false,"shares":65268,"price":14.8,"value":965966.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Represented by ADSs. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 8, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price per ordinary share ($177.58 per ADS). These shares were sold in multiple transactions at prices ranging from $177.01 per ADS (or $14.75 per ordinary share) to $177.90 per ADS (or $14.83 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":514176,"source":{"system":"sec-edgar","filing":"0000899243-19-013509","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319013509/doc4.xml","form_type":"4"}},{"id":3527515,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, North America"}}],"security":"Ordinary Shares","published_at":"2019-05-14T21:00:24.000Z","date":"2019-05-10","kind":"sale","acquired":false,"shares":81156,"price":14.7,"value":1192993.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Represented by ADSs. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 8, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price per ordinary share ($176.40 per ADS). These shares were sold in multiple transactions at prices ranging from $175.99 per ADS (or $14.67 per ordinary share) to $176.87 per ADS (or $14.74 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":579444,"source":{"system":"sec-edgar","filing":"0000899243-19-013509","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319013509/doc4.xml","form_type":"4"}},{"id":3527514,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, North America"}}],"security":"Ordinary Shares","published_at":"2019-05-14T21:00:24.000Z","date":"2019-05-10","kind":"sale","acquired":false,"shares":117876,"price":14.63,"value":1724525.88,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Represented by ADSs. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 8, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price per ordinary share ($175.57 per ADS). These shares were sold in multiple transactions at prices ranging from $174.99 per ADS (or $14.58 per ordinary share) to $175.98 per ADS (or $14.67 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":660600,"source":{"system":"sec-edgar","filing":"0000899243-19-013509","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319013509/doc4.xml","form_type":"4"}},{"id":3527513,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, North America"}}],"security":"Ordinary Shares","published_at":"2019-05-14T21:00:24.000Z","date":"2019-05-10","kind":"exercise","acquired":true,"shares":192755,"price":3.72,"value":717048.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares of the Issuer (\"ADS\"). Each ADS represents twelve ordinary shares of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The exercise price was previously reported to be $3.3461 on the Reporting Person's form 3 filed with the SEC on October 1, 2018 due to an administrative error."}],"balance_after":778476,"source":{"system":"sec-edgar","filing":"0000899243-19-013509","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319013509/doc4.xml","form_type":"4"}},{"id":3527512,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, North America"}}],"security":"Ordinary Shares","published_at":"2019-05-14T21:00:24.000Z","date":"2019-05-10","kind":"exercise","acquired":true,"shares":75369,"price":10.61,"value":799665.09,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares of the Issuer (\"ADS\"). Each ADS represents twelve ordinary shares of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The exercise price was previously reported to be $8.7364 on the Reporting Person's form 3 filed with the SEC on October 1, 2018 due to an administrative error."}],"balance_after":585721,"source":{"system":"sec-edgar","filing":"0000899243-19-013509","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319013509/doc4.xml","form_type":"4"}},{"id":3527511,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, North America"}}],"security":"Ordinary Shares","published_at":"2019-05-14T21:00:24.000Z","date":"2019-05-10","kind":"exercise","acquired":true,"shares":403804,"price":0.0013,"value":524.9452,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares of the Issuer (\"ADS\"). Each ADS represents twelve ordinary shares of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.30 U.S. Dollars as of May 10, 2019."}],"balance_after":510352,"source":{"system":"sec-edgar","filing":"0000899243-19-013509","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319013509/doc4.xml","form_type":"4"}},{"id":3531502,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2019-05-10T20:54:42.000Z","date":"2019-05-09","kind":"grant","acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the stock option shall vest on the one year anniversary, May 9, 2020, subject to Mr. Gangolli's Continuous Service (as defined in the Plan) through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy."}],"balance_after":9000,"derivative":{"exercise_price":12.82,"expiration_date":"2029-05-08","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001479290-19-000056","document":"wf-form4_155753606689715.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929019000056/wf-form4_155753606689715.xml","form_type":"4"}},{"id":3531501,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-10T20:54:42.000Z","date":"2019-05-09","kind":"grant","acquired":true,"shares":4500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an annual restricted stock award (the \"RSA\") granted pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the \"Compensation Policy\").  The shares underlying the RSA shall vest on the one year anniversary, May 9, 2020, subject to Mr. Gangolli's Continuous Service (as defined the Issuer's 2014 Equity Incentive Plan (the \"Plan\")) through such vesting date."}],"balance_after":10500,"source":{"system":"sec-edgar","filing":"0001479290-19-000056","document":"wf-form4_155753606689715.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929019000056/wf-form4_155753606689715.xml","form_type":"4"}},{"id":3608588,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-03-06T22:53:02.000Z","date":"2019-03-01","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were awarded on March 1, 2019 and vest monthly over a three-year period."}],"balance_after":20000,"derivative":{"exercise_price":22.75,"exercise_date":"2022-03-01","expiration_date":"2029-03-01","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-19-017476","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711279/000120919119017476/doc4.xml","form_type":"4"}},{"id":3626039,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, North America"}}],"security":"Stock Options","published_at":"2019-02-28T17:09:20.000Z","date":"2019-02-26","kind":"exercise","acquired":false,"shares":11256,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.29 U.S. Dollars as of February 26, 2019."}],"balance_after":6,"derivative":{"exercise_price":0.0013,"exercise_date":"2019-02-26","expiration_date":"2020-03-15","underlying":"Ordinary Shares","underlying_shares":11256},"source":{"system":"sec-edgar","filing":"0000899243-19-005266","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319005266/doc4.xml","form_type":"4"}},{"id":3626038,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, North America"}}],"security":"Ordinary Shares","published_at":"2019-02-28T17:09:20.000Z","date":"2019-02-26","kind":"sale","acquired":false,"shares":48,"price":12.37,"value":593.76,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"These ordinary shares are represented by ADSs."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is price per ordinary share converted from price per ADS."}],"balance_after":106548,"source":{"system":"sec-edgar","filing":"0000899243-19-005266","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319005266/doc4.xml","form_type":"4"}},{"id":3626037,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, North America"}}],"security":"Ordinary Shares","published_at":"2019-02-28T17:09:20.000Z","date":"2019-02-26","kind":"sale","acquired":false,"shares":5952,"price":12.45,"value":74102.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"These ordinary shares are represented by ADSs."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is price per ordinary share converted from price per ADS."}],"balance_after":106596,"source":{"system":"sec-edgar","filing":"0000899243-19-005266","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319005266/doc4.xml","form_type":"4"}},{"id":3626036,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, North America"}}],"security":"Ordinary Shares","published_at":"2019-02-28T17:09:20.000Z","date":"2019-02-26","kind":"exercise","acquired":true,"shares":11256,"price":0.0013,"value":14.6328,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Exercise of stock options. Following the exercise, these shares were converted into 938 American Depositary Shares of the Issuer (\"ADS\"). Each ADS represents twelve ordinary shares of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.29 U.S. Dollars as of February 26, 2019."}],"balance_after":112548,"source":{"system":"sec-edgar","filing":"0000899243-19-005266","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319005266/doc4.xml","form_type":"4"}},{"id":3937012,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2018-05-11T20:27:39.000Z","date":"2018-05-10","kind":"grant","acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the stock option shall vest on the one year anniversary, May 10, 2019, subject to Mr. Gangolli's Continuous Service (as defined in the Plan) through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy."}],"balance_after":6000,"derivative":{"exercise_price":29.15,"expiration_date":"2028-05-09","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001479290-18-000078","document":"wf-form4_152608484494007.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929018000078/wf-form4_152608484494007.xml","form_type":"4"}},{"id":3937011,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-05-11T20:27:39.000Z","date":"2018-05-10","kind":"grant","acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an annual restricted stock award (the \"RSA\") granted pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the \"Compensation Policy\").  The shares underlying the RSA shall vest on the one year anniversary, May 10, 2019, subject to Mr. Gangolli's Continuous Service (as defined the Issuer's 2014 Equity Incentive Plan (the \"Plan\")) through such vesting date."}],"balance_after":6000,"source":{"system":"sec-edgar","filing":"0001479290-18-000078","document":"wf-form4_152608484494007.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929018000078/wf-form4_152608484494007.xml","form_type":"4"}},{"id":4322695,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-05-12T19:48:30.000Z","date":"2017-05-11","kind":"grant","acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the stock option shall vest on the one year anniversary,  May 11, 2018, subject to Mr. Gangolli's Continuous Service (as defined in the Plan) through such vesting date. The stock option represents an annual option grant pursuant to the Compensation Policy."}],"balance_after":6000,"derivative":{"exercise_price":20.9,"expiration_date":"2027-05-10","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001209191-17-032206","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000120919117032206/doc4.xml","form_type":"4"}},{"id":4322694,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-05-12T19:48:30.000Z","date":"2017-05-11","kind":"grant","acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an annual restricted stock award (the \"RSA\") granted pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the \"Compensation Policy\").  The shares underlying the RSA shall vest on the one year anniversary, May 11, 2018, subject to Mr. Gangolli's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan (the \"Plan\")) through such vesting date."}],"balance_after":3000,"source":{"system":"sec-edgar","filing":"0001209191-17-032206","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000120919117032206/doc4.xml","form_type":"4"}}]}